Renin-angiotensin system at the heart of COVID-19 pandemic.
Biochimie. 2020 Apr 16;174:30-33.
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.
N Engl J Med. 2020 Apr 23;382(17):1653-1659.
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
Drug Dev Res. 2020 Mar 4.
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic.
Nat Rev Nephrol. 2020 Apr 3.
Might renin–angiotensin system blockers play a role in the COVID-19 pandemic?
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 14. pii: pvaa030
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
J Virol. 2020 Mar 17;94(7). pii: e00127-20
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell 181, 1–10, April 16, 2020.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.
Science. 2020 Mar 27;367(6485):1444-1448
Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.
Clin Pharmacol Ther. 2020 Apr 22.
Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.
Cardiovasc Res. 2020 Apr 17.
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.
High Blood Press Cardiovasc Prev. 2020 Apr;27(2):105-108.
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Elife. 2020 Apr 6;9. pii: e57278.